Kiora's KIO-301 shows vision restoration in blind RP patients in Phase 1b

KIORA PHARMACEUTICALS INC

Preliminary Phase 1b ABACUS data: KIO-301 improved light perception in patients with no light perception.
Patient-reported light/dark contrast perception improved at days 7, 14, and 29 post-injection.
fMRI showed significantly increased V1 visual cortex activity at days 3 and 15 vs. baseline.
Quality-of-life score increased 6 points (clinically meaningful threshold is 2–4 points).
No adverse events reported; dose escalation and full results expected later in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.